Open Access

MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis

  • Authors:
    • Liang-Kai Hu
    • Jian-Qing Chen
    • Hao Zheng
    • Yuan-Ping Tao
    • Yuan Yang
    • Xuan-Fu Xu
  • View Affiliations

  • Published online on: October 11, 2021     https://doi.org/10.3892/etm.2021.10865
  • Article Number: 1430
  • Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nonalcoholic fatty liver disease (NAFLD) is a complex type of liver disease that represents an important global health threat. The mechanistic basis of this disease remains incompletely understood. The present study sought to explore whether microRNA (miR)-506-3p served a functional role in the onset and/or progression of NAFLD. To that end, high levels of glucose were used to treat liver cancer cell lines (HepG2 and Huh7) to model hepatic steatosis, and the expression levels of miR-506-3p and its downstream target genes were assessed. The cells of this hepatic steatosis model were transfected with miR-506-3p mimic molecules to explore the effect of miR-506-3p overexpression on cell viability, target gene expression and AMP-activated protein kinase (AMPK) phosphorylation. Via bioinformatics approaches, sirtuin 1 (SIRT1) was identified as a potential miR-506-3p target gene with relevance in NAFLD, and this interaction was confirmed via luciferase reporter assay. In the hepatic steatosis model of the present study, miR-506-3p expression level was significantly increased, whereas SIRT1 mRNA/protein levels and AMPK phosphorylation levels were markedly decreased. Transfection of the cells with miR-506-3p mimics led to significant SIRT1 downregulation, while miR-506-3p inhibitor molecules exhibited the opposite effect, with similar trends observed in the phosphorylation status of AMPK. These results suggested that miR-506-3p can inhibit SIRT1 expression and associated AMPK phosphorylation in HepG2 and Huh7 cells in an in vitro hepatic steatosis model system. These data indicated that the miR-506-3p/SIRT1/AMPK axis may be valuable as a therapeutic target in patients affected by NAFLD.
View Figures
View References

Related Articles

Journal Cover

December-2021
Volume 22 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hu L, Chen J, Zheng H, Tao Y, Yang Y and Xu X: MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis. Exp Ther Med 22: 1430, 2021
APA
Hu, L., Chen, J., Zheng, H., Tao, Y., Yang, Y., & Xu, X. (2021). MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis. Experimental and Therapeutic Medicine, 22, 1430. https://doi.org/10.3892/etm.2021.10865
MLA
Hu, L., Chen, J., Zheng, H., Tao, Y., Yang, Y., Xu, X."MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis". Experimental and Therapeutic Medicine 22.6 (2021): 1430.
Chicago
Hu, L., Chen, J., Zheng, H., Tao, Y., Yang, Y., Xu, X."MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis". Experimental and Therapeutic Medicine 22, no. 6 (2021): 1430. https://doi.org/10.3892/etm.2021.10865